Who Paid My Doc
Jimmy Mali
Physical Medicine & Rehabilitation Durham, NC Medical Doctor
NPI 1669676318 CMS profile 121649
120 William Penn Plz, Durham, NC 27704
General payments
$20,405
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jimmy Mali of Durham, NC is reported in the CMS Open Payments database as having received $20,405 across 52 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $176 | 5 | |
| 2024 | General | $1,295 | 14 | |
| 2023 | General | $1,579 | 6 | |
| 2022 | General | $43 | 1 | |
| 2020 | General | $8,227 | 4 | |
| 2019 | General | $9,085 | 22 |
Beside peers
- Jimmy Mali
- Physical Medicine & Rehabilitation median
- Middle half of Physical Medicine & Rehabilitation
- National median
In program year 2025, general payments to Jimmy Mali were reported at $176. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.
Show as a table
| Year | Jimmy Mali | Physical Medicine & Rehabilitation median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $9,085 | $133 | $45–$390 | $163 |
| 2020 | $8,227 | $88 | $29–$272 | $114 |
| 2021 | $0 | $116 | $33–$360 | $132 |
| 2022 | $43 | $123 | $40–$378 | $149 |
| 2023 | $1,579 | $131 | $43–$396 | $160 |
| 2024 | $1,295 | $141 | $45–$409 | $164 |
| 2025 | $176 | $139 | $48–$410 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
258
Drug cost
$27,265
Branded share of claims
21.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Relistor Methylnaltrexone Bromide | Brand | 11 | $24,888 | |
| Gabapentin | Generic | 47 | $566 | |
| Pregabalin | Generic | 25 | $531 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 21 | $460 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 23 | $457 | |
| Cyclobenzaprine Hcl | Generic | 25 | $132 | |
| Duloxetine Hcl | Generic | 11 | $73 | |
| Tizanidine Hcl | Generic | 13 | $61 | |
| Alprazolam | Generic | 70 | $54 | |
| Meloxicam | Generic | 12 | $42 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 78 billing codesPaid by Medicare
$255,830
Medicare patients
617
Services billed
37,829
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 30% | |
| Depression | 30% | |
| Chronic kidney disease | 25% | |
| Ischemic heart disease | 23% | |
| Osteoporosis | 19% | |
| COPD | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 373 | 28,703 | $8,195 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 451 | 4,544 | $3,445 |
| Injection, ropivacaine hydrochloride, 1 mg J2795 | Office | 16 | 1,495 | $76 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 29 | 535 | $49 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
52 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Physical Medicine & Rehabilitation in North Carolina
Andrew Sumich
Physical Medicine & Rehabilitation · Charlotte, NC
Patrick O Brien
Physical Medicine & Rehabilitation · Raleigh, NC
Elizabeth Bagsby
Physical Medicine & Rehabilitation · Greenville, NC
Krishna Bhat
Physical Medicine & Rehabilitation · Sanford, NC
Jasbir Dhaliwal
Physical Medicine & Rehabilitation · Sanford, NC
Jerome Watson
Physical Medicine & Rehabilitation · Statesville, NC
Related records
Physical Medicine & Rehabilitation in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Physical Medicine & Rehabilitation
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.